MC
PDLI

Moors & Cabot’s PDL BioPharma, Inc. PDLI Stock Holding History

Moors & Cabot’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,600
Closed -$85K – 570
2014
Q3 		$85K Buy
11,600
+1,300
+13% +$12.1K 0.01% 519
2014
Q2 		$102K Buy
+10,300
New +$91.8K 0.02% 514

Other funds holding PDLI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Moors & Cabot's PDLI Position: Q4 2014 in Review

Moors & Cabot sold out of PDL BioPharma, Inc. (PDLI) in Q4 2014, closing a stake of 11,600 shares — an estimated $85K sold.

Moors & Cabot first reported a position in PDLI in Q2 2014 and held it in 2 quarters. The position peaked at $102K in Q2 2014. 223 funds tracked by Wall St. Rank hold PDLI as of Q4 2014.

  • Moors & Cabot reported no remaining PDL BioPharma, Inc. position as of Q4 2014 after selling out during the quarter.
  • Moors & Cabot sold 11,600 PDL BioPharma, Inc. shares in Q4 2014, an estimated $85K.
  • Moors & Cabot first reported a position in PDL BioPharma, Inc. in Q2 2014 and held it in 2 quarters.
  • Moors & Cabot's PDL BioPharma, Inc. position peaked at $102K in Q2 2014.
  • 223 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2014.

Based on Moors & Cabot's 13F filing for Q4 2014, filed 17 Feb 2015.